(1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial

(1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial

Abstract Background (1,3)-β-d-Glucan has been widely used in clinical practice for the diagnosis of invasive Candida infections. However, such serum biomarker showed potential to guide antimicrobial therapy in order to reduce the duration of empirical antifungal treatment in critically ill septic pa...

Full description

Bibliographic Details
Main Authors: Gennaro De Pascale, Brunella Posteraro, Sonia D’Arrigo, Giorgia Spinazzola, Rita Gaspari, Giuseppe Bello, Luca Maria Montini, Salvatore Lucio Cutuli, Domenico Luca Grieco, Valentina Di Gravio, Giulia De Angelis, Riccardo Torelli, Elena De Carolis, Mario Tumbarello, Maurizio Sanguinetti, Massimo Antonelli
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Critical Care
Subjects:
Sepsis
Candida infection
Biomarker
(1,3)-β-d-Glucan
Antifungal therapy
Online Access:http://link.springer.com/article/10.1186/s13054-020-03265-y

Internet

http://link.springer.com/article/10.1186/s13054-020-03265-y

Similar Items